The survey findings, published in the Journal of Managed Care & Specialty Pharmacy, showed 62% of respondents predict that the number of active drug shortages will rise by more than 25% within five years, potentially worsening patient access to critical medications.
In addition, 92% of respondents reported they anticipate AI will be more integrated into more than half of prior authorization reviews.
Another pressing concern for participants was the rise in drug costs, with 54% expecting at least half of U.S. states to establish drug-affordability boards. Additionally, 97% foresee a 25% surge in GLP-1 therapies.
The foundation is the philanthropic arm of the AMCP.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
